Kawasaki M, Nakanishi Y, Yatsunami J, Takayama K, Ochiai S, Xinhai P, Kuwano K, Hara N
Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Cancer J Sci Am. 1996 Jul-Aug;2(4):217-20.
Although resistance to chemotherapy is a major problem in cancer treatment, there is no predictor of treatment response. Recent reports suggest that p53 status may provide a genetic basis for drug resistance.
Transbronchial biopsy specimens from 18 patients with non-small cell lung cancer were evaluated for p53 expression using anti-p53 antibody (DO-1). After biopsy, these patients received more than two courses of identical chemotherapy including cisplatin, carboplatin, and vindesine.
Ten of 18 (56%) patients responded to chemotherapy. The accumulation of p53 protein was detected in 10 of 18 (56%) patients. Positive staining for p53 was significantly correlated with unresponsiveness to chemotherapy. Other factors, including gender, performance status, body weight loss, serum albumin, and serum LDH, did not correlate with the immunohistochemical expression of p53.
These results suggest that immunostaining with p53 can be a predictor of the response to chemotherapy in non-small cell lung cancer. Further studies are needed to confirm the relationship between p53 expression and chemosensitivity.
尽管化疗耐药是癌症治疗中的一个主要问题，但目前尚无治疗反应的预测指标。最近的报告表明，p53状态可能为耐药提供遗传基础。
使用抗p53抗体（DO-1）对18例非小细胞肺癌患者的经支气管活检标本进行p53表达评估。活检后，这些患者接受了包括顺铂、卡铂和长春地辛在内的两个以上疗程的相同化疗。
18例患者中有10例（56%）对化疗有反应。18例患者中有10例（56%）检测到p53蛋白积累。p53阳性染色与化疗无反应显著相关。其他因素，包括性别、体能状态、体重减轻、血清白蛋白和血清乳酸脱氢酶，与p53的免疫组化表达无关。
这些结果表明，p53免疫染色可作为非小细胞肺癌化疗反应的预测指标。需要进一步研究以证实p53表达与化疗敏感性之间的关系。
